Physician profile
Robert C Franklin
NPI 1679516967
$15,604.26
in general payments reported to CMS, 2019-2025
47 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $2,253 · 2021: $2,844 · 2022: $2,426 · 2023: $2,155 · 2024: $1,921 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,713 · Education: $60.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,713.29 |
| Education | $60.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,376.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,718.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,285.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,144.28 | 2019-2025 | |
| Glaxosmithkline, LLC. | $959.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $813.28 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.28 | 2019-2025 | Jardiance |
| Amgen INC. | $730.17 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $687.57 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $659.12 | 2019-2025 | |
| Amarin Pharma, INC. | $558.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $374.84 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Abbvie INC. | $373.54 | 2019-2024 | |
| Astellas Pharma US INC | $367.72 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $353.71 | 2021-2025 | Rexulti |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.